Advertisement
Journal Home
Search for

Volume 35, Issue 12, Pages 1753-1765 (December 2007)


View previous. 2 of 16 View next.

The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration

Carmella van de Vena, Daniel Collinsd, M. Brigid Bradleya, Erin Morrisa, Mitchell S. CairoabcCorresponding Author Informationemail address

Received 7 June 2007; received in revised form 8 August 2007; accepted 13 August 2007. published online 18 October 2007.

Stem cells have been isolated from human embryos, fetal tissue, umbilical cord blood (UCB), and also from “adult” sources. Adult stem cells are found in many tissues of the body and are capable of maintaining, generating, and replacing terminally differentiated cells. A source of pluripotent stem cells has been recently identified in UCB that can also differentiate across tissue lineage boundaries into neural, cardiac, epithelial, hepatocytic, and dermal tissue. Thus, UCB may provide a future source of stem cells for tissue repair and regeneration. Its widespread availability makes UCB an attractive source for tissue regeneration. UCB-derived stem cells offer multiple advantages over adult stem cells, including their immaturity, which may play a significant role in reduced rejection after transplantation into a mismatched host and their ability to produce larger quantities of homogenous tissue or cells. While research with embryonic stem cells continues to generate considerable controversy, human umbilical stem cells provide an alternative cell source that has been more ethically acceptable and appears to have widespread public support. This review will summarize the in vitro and in vivo studies examining UCB stem cells and their potential use for therapeutic application for nonhematopoietic tissue and cell regeneration.

a Department of Pediatrics, Columbia University and Morgan Stanley Children's Hospital New York-Presbyterian, New York, NY., USA

b Department of Medicine, Columbia University and Morgan Stanley Children's Hospital New York-Presbyterian, New York, NY., USA

c Department of Pathology, Columbia University and Morgan Stanley Children's Hospital New York-Presbyterian, New York, NY., USA

d BioE, St. Paul, Minn., USA

Corresponding Author InformationOffprint request to: Mitchell S. Cairo, M.D., Departments of Pediatrics, Medicine, and Pathology, Division of Pediatric Blood and Marrow Transplantation, Morgan Stanley Children's Hospital of NewYork-Presbyterian, Columbia University, 3959 Broadway, CHN 10-03, New York, NY 10032

PII: S0301-472X(07)00526-7

doi:10.1016/j.exphem.2007.08.017


View previous. 2 of 16 View next.